Investment
Features
FeesSafety
Academy
More
Pluang+

Bitcoin ETF inflows hit $626M in early August, with BlackRock dominating; price eyes $76K breakout.

Market News
07 Aug 2026
Blockonomi
View Source
Bullish
Bitcoin ETF inflows hit $626M in early August, with BlackRock dominating; price eyes $76K breakout.

Bitcoin ETF inflows surged to about $626 million from August 3 to 5, led by BlackRock's IBIT fund which collected roughly $479 million. Large Bitcoin holders, or whales, have accumulated over 20,000 BTC since late July, indicating strong institutional interest. Despite this, Bitcoin's price remains below key resistance near $66,800, preventing a clear breakout. A confirmed move above this level could push Bitcoin toward $76,000, while support sits near $63,321. Regulatory uncertainty and mixed buying patterns suggest some demand may be tactical rather than broad market conviction.

More News

SailPoint Q2 revenue slightly misses estimates but shows strong ARR growth and EPS beat.

SailPoint Q2 revenue slightly misses estimates but shows strong ARR growth and EPS beat.

SailPoint reported Q2 2026 earnings with revenue of $308.81 million, slightly below estimates but up 17% year-over-year. Adjusted EPS of $0.09 beat analyst expectations by 12.5%, reflecting improved profitability. The company showed strong subscripti...

Company Fundamentals
Neutral
1 hour ago
The Cooper Companies forecast Q3 EPS of $1.12 and $1.10B revenue, with an analyst raising price target to $80.

The Cooper Companies forecast Q3 EPS of $1.12 and $1.10B revenue, with an analyst raising price target to $80.

The Cooper Companies is set to report its Q3 2026 earnings with analysts expecting earnings per share (EPS) of $1.12 and revenue of $1.10 billion, both showing growth from the previous year. Despite a recent 2.7% drop in stock price to $67.69, an ana...

Company Fundamentals
Bullish
1 hour ago
Intellia Therapeutics gains as FDA grants Priority Review for HAE treatment and analyst hikes price target.

Intellia Therapeutics gains as FDA grants Priority Review for HAE treatment and analyst hikes price target.

Intellia Therapeutics saw a boost after Wedbush analyst raised its price target to $13, signaling potential upside from its current $12.64 share price. The FDA granted Priority Review to Intellia's lonvo-z treatment for Hereditary Angioedema, with a ...

Analyst Insights
Bullish
2 hours ago
Signet Jewelers beats Q2 earnings estimates, raises full-year profit forecast, shares jump 14%.

Signet Jewelers beats Q2 earnings estimates, raises full-year profit forecast, shares jump 14%.

Signet Jewelers reported Q2 fiscal 2027 earnings of $2.19 per share, surpassing analyst estimates of $1.69 by nearly 30%, marking its sixth consecutive quarter of earnings beats. Although revenue slightly missed expectations at $1.528 billion versus ...

Company Fundamentals
Bullish
2 hours ago
UBS raises ABM Industries price target to $51.50 after strong earnings and revenue growth.

UBS raises ABM Industries price target to $51.50 after strong earnings and revenue growth.

UBS increased its price target for ABM Industries to $51.50 following the company's strong quarterly earnings and revenue growth. ABM reported a 4.2% revenue increase to $2.32 billion and a 19% rise in net income to $49.7 million, alongside strong ca...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App